Bausch Health Companies Inc. Stock
$6.46
0.78%
yesterday
NYSE,
Jun 27, 10:10 pm CET
Bausch Health Companies Inc. Stock price
$6.46
+1.87
40.74%
1M
-1.19
15.56%
6M
-1.60
19.85%
YTD
-0.43
6.24%
1Y
-2.22
25.58%
3Y
-11.73
64.49%
5Y
-213.85
97.07%
10Y
-8.73
57.48%
20Y
NYSE,
Closing price Fri, Jun 27 2025
+0.05
0.78%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
Basic
Market capitalization
$2.4b
Enterprise Value
$22.7b
Net debt
$20.4b
Cash
$1.1b
Shares outstanding
369.5m
Valuation (TTM | estimate)
P/E
negative | 1.42
P/S
0.24 | 0.24
EV/Sales
2.34 | 2.28
EV/FCF
18.69
P/B
negative
Dividends
DPS
Yield 1Y | 5Y
- | -
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
-
Financials (TTM | estimate)
Revenue
$9.7b | $10.0b
EBITDA
$2.9b | $3.5b
EBIT
$1.9b
Net Income
$-40.0m | $1.7b
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
8.53% | 3.71%
EBITDA
5.85% | 19.55%
EBIT
10.77%
Net Income
91.21% | 3,746.35%
Free Cash Flow
54.90%
Margin (TTM | estimate)
Gross
70.78%
EBITDA
29.91% | 35.10%
EBIT
19.03%
Net
-0.41% | 16.80%
Free Cash Flow
12.50%
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
9 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
9 Analysts have issued a Bausch Health Companies Inc. forecast:
Hold
56%
Sell
44%
Financial data from Bausch Health Companies Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | 9,731 9,731 |
9%
9%
|
|
| Gross Profit | 6,888 6,888 |
8%
8%
|
|
| EBITDA | 2,911 2,911 |
6%
6%
|
EBIT (Operating Income) EBIT | 1,852 1,852 |
11%
11%
|
| Net Profit | -40 -40 |
91%
91%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
Business Wire
●
one day ago
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate pri...
Positive
24/7 Wall Street
●
4 days ago
We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.
Positive
Barrons
●
6 days ago
John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,700 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
